WAVE Life Sciences Ltd has a consensus price target of $11.71, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Mizuho, and RBC Capital on April 1, 2024, March 12, 2024, and March 7, 2024. With an average price target of $13.67 between Truist Securities, Mizuho, and RBC Capital, there's an implied 172.79% upside for WAVE Life Sciences Ltd from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/01/2024 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 239.32% | Truist Securities | Joon Lee | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
03/12/2024 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 279.24% | Mizuho | Salim Syed | $10 → $19 | Maintains | Buy | Get Alert |
03/07/2024 | WVE | Buy Now | WAVE Life Sciences | $5.01 | -0.2% | RBC Capital | Luca Issi | → $5 | Reiterates | Sector Perform → Sector Perform | Get Alert |
03/07/2024 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 199.4% | HC Wainwright & Co. | Andrew Fein | $8 → $15 | Maintains | Buy | Get Alert |
12/19/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 139.52% | Leerink Partners | Mani Foroohar | → $12 | Upgrade | Market Perform → Outperform | Get Alert |
08/04/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 59.68% | HC Wainwright & Co. | Andrew Fein | → $8 | Reiterates | Buy → Buy | Get Alert |
07/05/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 39.72% | Raymond James | Steven Seedhouse | → $7 | Initiates | → Outperform | Get Alert |
06/23/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 239.32% | Truist Securities | Joon Lee | → $17 | Reiterates | Buy → Buy | Get Alert |
05/24/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 99.6% | Mizuho | Salim Syed | $13 → $10 | Maintains | Buy | Get Alert |
05/24/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 59.68% | HC Wainwright & Co. | Andrew Fein | → $8 | Reiterates | Buy → Buy | Get Alert |
05/04/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | -0.2% | RBC Capital | Luca Issi | → $5 | Reiterates | → Sector Perform | Get Alert |
04/14/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 159.48% | Mizuho | Salim Syed | → $13 | Reiterates | → Buy | Get Alert |
03/23/2023 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 59.68% | HC Wainwright & Co. | Andrew Fein | → $8 | Reiterates | → Buy | Get Alert |
12/14/2022 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 39.72% | SVB Leerink | Mani Foroohar | $2 → $7 | Maintains | Market Perform | Get Alert |
11/11/2022 | WVE | Buy Now | WAVE Life Sciences | $5.01 | -0.2% | RBC Capital | Luca Issi | $8 → $5 | Maintains | Sector Perform | Get Alert |
05/13/2022 | WVE | Buy Now | WAVE Life Sciences | $5.01 | 59.68% | HC Wainwright & Co. | Andrew Fein | $10 → $8 | Maintains | Buy | Get Alert |
05/13/2022 | WVE | Buy Now | WAVE Life Sciences | $5.01 | -40.12% | SVB Leerink | Mani Foroohar | $7 → $3 | Maintains | Market Perform | Get Alert |
The latest price target for WAVE Life Sciences (NASDAQ: WVE) was reported by Truist Securities on April 1, 2024. The analyst firm set a price target for $17.00 expecting WVE to rise to within 12 months (a possible 239.32% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for WAVE Life Sciences (NASDAQ: WVE) was provided by Truist Securities, and WAVE Life Sciences reiterated their buy rating.
The last upgrade for WAVE Life Sciences Ltd happened on December 19, 2023 when Leerink Partners raised their price target to $12. Leerink Partners previously had a market perform for WAVE Life Sciences Ltd.
There is no last downgrade for WAVE Life Sciences.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of WAVE Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for WAVE Life Sciences was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
While ratings are subjective and will change, the latest WAVE Life Sciences (WVE) rating was a reiterated with a price target of $17.00 to $17.00. The current price WAVE Life Sciences (WVE) is trading at is $5.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.